One ticker, one page: health score, red flags, fundamentals, who’s buying, cash & dilution, and the latest catalyst — every module built from SEC filings, ready to print or share.
start from a preset — you get the bundle, then edit it
or pick exactly what you want — 5 selected
These add one extra lookup each — still fine to combine.
Heavy modules — each one runs on its own. Checking one clears the rest, because it reads several filings live and would otherwise time the page out.
Your selection lives in the link, so a built report is shareable and bookmarkable. Educational information from public filings — not investment advice.
Assembling AXON’s research report…
Pulling SEC filings
Parsing XBRL fundamentals
Scoring quality, value & momentum
Checking who’s buying
Rendering
AXON AXON ENTERPRISE, INC.
Research report · from SEC EDGAR · close 2026-11-02
$425.43 -0.5%
$34.56B mkt cap
Close: REPORTED End-of-day closing price; as of 2026-11-02. No single source document identified.
Market cap: DERIVED Last close times filed shares outstanding, dei:EntityCommonStockSharesOutstanding; as of close 2026-11-02; count as of 2026-07-31; Form 10-Q 0001628280-26-053646, filed 2026-08-06.
AXON ENTERPRISE, INC. (AXON) is a $34.56B company. Revenue is $2.78B (+33.5% y/y) at a 4% net margin. It is profitable. Our health score is C (68/100). No major red flags on file. Held by 2 tracked funds. It funds itself; low dilution risk.
Market cap: DERIVED Last close times filed shares outstanding, dei:EntityCommonStockSharesOutstanding; as of close 2026-11-02; count as of 2026-07-31; Form 10-Q 0001628280-26-053646, filed 2026-08-06.
Revenue and growth: REPORTED SEC XBRL companyfacts, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; as of FY ending 2025-12-31; Form 10-K 0001628280-26-011360, filed 2026-02-25.
Net margin: UNVALIDATED Net income over revenue, from SEC XBRL companyfacts; as of FY ending 2025-12-31. Method not verified against an independent source.
Net income: REPORTED SEC XBRL companyfacts, us-gaap:NetIncomeLoss; as of FY ending 2025-12-31; Form DEF 14A 0001628280-26-025521, filed 2026-04-16.
Health score: UNVALIDATED StockTools.ai health score, from SEC XBRL companyfacts and end-of-day prices; as of scores FY ending 2025-12-31; cash as of 2026-06-30; trend at close 2026-11-02. Method not verified against an independent source.
REPORTED SEC XBRL companyfacts, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; as of FY ending 2025-12-31; Form 10-K 0001628280-26-011360, filed 2026-02-25.
Net income
$124.7M
REPORTED SEC XBRL companyfacts, us-gaap:NetIncomeLoss; as of FY ending 2025-12-31; Form DEF 14A 0001628280-26-025521, filed 2026-04-16.
Net margin
4.5%
UNVALIDATED Net income over revenue, from SEC XBRL companyfacts; as of FY ending 2025-12-31. Method not verified against an independent source.
EPS (diluted)
$1.51
REPORTED SEC XBRL companyfacts, us-gaap:EarningsPerShareDiluted; as of FY ending 2025-12-31; Form 10-K 0001628280-26-011360, filed 2026-02-25.
Piotroski F
5/9
UNVALIDATED Piotroski F-Score, computed from SEC XBRL companyfacts; as of FY ending 2025-12-31, against FY ending 2024-12-31.
✓ No major red flags from our filing-based checks.
who's buying
Insider buys / sells
0 / 6
DERIVED SEC Form 4, open-market purchases (P) and sales (S); as of filed 2026-08-11 to 2026-09-14.
Congress buys
0
DERIVED Periodic transaction reports filed under the STOCK Act; as of no report in the window read. No single source document identified; no as-of date carried.
13F fund holders
2
DERIVED SEC Form 13F-HR, the funds we track; as of quarter ended 2026-06-30. No single source document identified.
DERIVED SEC XBRL companyfacts, balance sheet, us-gaap:CashAndCashEquivalentsAtCarryingValue; as of 2026-06-30.
Operating cash flow
$211.3M
REPORTED SEC XBRL companyfacts, cash flow statement, us-gaap:NetCashProvidedByUsedInOperatingActivities; as of FY ending 2025-12-31.
Going concern
None
REPORTED SEC full-text search for "substantial doubt" in 10-K and 10-Q filings; as of filed 2025-07-31 to 2026-11-03.
Assembled from SEC EDGAR (XBRL, Form 4, 13F, filings), STOCK Act disclosures, and end-of-day prices. Each figure prints its own source and the date it is true as of beneath it, with REPORTED for a figure the source published and DERIVED or UNVALIDATED for our arithmetic; nothing is fabricated or predicted. Filings lag 40 to 90 days. Educational, not investment advice. Generated 2026-11-03 by stocktools.ai.
Insider counts: DERIVED SEC Form 4, open-market purchases (P) and sales (S); as of filed 2026-08-11 to 2026-09-14.
Congress counts: DERIVED Periodic transaction reports filed under the STOCK Act; as of no report in the window read. No single source document identified; no as-of date carried.
Fund holders: DERIVED SEC Form 13F-HR, the funds we track; as of quarter ended 2026-06-30. No single source document identified.
Cash need: DERIVED Operating cash flow and cash on hand, from SEC XBRL companyfacts; as of cash as of 2026-06-30; operating cash flow over FY ending 2025-12-31.
Method not verified against an independent source.
Altman Z
safe
UNVALIDATED Altman Z-Score, computed from SEC XBRL companyfacts; as of FY ending 2025-12-31, against FY ending 2024-12-31. Method not verified against an independent source.